Terms ending in 2042
Every in-force patent on Biogen MA Inc.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,029,870 | Medical Device Having Non-Filtered CSF Withdrawal Pathway In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,180,205 | O-GLYCOPROTEIN-2-Acetamido-2-Deoxy-3-D-GLUCOPYRANOSIDASE Inhibitors In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 11,607,529 | Fixation Devices for Catheters In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,758,525 | Combination Treatment Methods of Multiple Sclerosis In force · Medium confidence | Biogen MA Inc. | In force | Medium confidence | |
| US 11,904,128 | Fluid Delivery System In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,240,838 | Inhibiting Agents for Bruton's Tyrosine Kinase In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,429,487 | Neurofilament Protein for Guiding Therapeutic Intervention in Amyotrophic Lateral Sclerosis In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,319,679 | Morpholinyl, Piperazinyl, Oxazepanyl and Diazepanyl O-GLYCOPROTEIN-2-Acetamido-2-Deoxy-3-D-GLUCOPYRANOSIDASE Inhibitors In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 11,827,702 | Anti-Transferrin Receptor Antibodies and Uses Thereof In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| US 12,467,929 | Methods of Detecting UBE3A Protein In force · High confidence | Biogen MA Inc. | In force | High confidence | |
| 5 more term ends in 2042 · Pro | |||||
10 of 15 patents shown. Soonest term end first, then patent number.
Pro members see all 15.
14 of these are in force and held by Biogen MA Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.